Switching from tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study

C Orkin; E DeJesus; M Ramgopal; G Crofoot; P Ruane; A LaMarca; A Mills; B Vandercam; J de Wet; J Rockstroh; A Lazzarin; Bart Rijnders; D Podzamczer; A Thalme; M Stoeckle; D Porter; HC Liu; A Cheng; E Quirk; D SenGupta; H Cao

doi:10.1016/s2352-3018(17)30031-0

Switching from tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study

C Orkin, E DeJesus, M Ramgopal, G Crofoot, P Ruane, A LaMarca, A Mills, B Vandercam, J de Wet, J Rockstroh, A Lazzarin, Bart Rijnders, D Podzamczer, A Thalme, M Stoeckle, D Porter, HC Liu, A Cheng, E Quirk, D SenGuptaH Cao

Internal Medicine

Research output: Contribution to journal › Article › Academic › peer-review

62 Citations (Scopus)

Original language	Undefined/Unknown
Pages (from-to)	E195-E204
Journal	LANCET HIV
Volume	4
Issue number	5
DOIs	https://doi.org/10.1016/s2352-3018(17)30031-0
Publication status	Published - 2017

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/s2352-3018(17)30031-0

http://hdl.handle.net/1765/98233

Cite this

Orkin, C., DeJesus, E., Ramgopal, M., Crofoot, G., Ruane, P., LaMarca, A., Mills, A., Vandercam, B., de Wet, J., Rockstroh, J., Lazzarin, A., Rijnders, B., Podzamczer, D., Thalme, A., Stoeckle, M., Porter, D., Liu, HC., Cheng, A., Quirk, E., ... Cao, H. (2017). Switching from tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study. LANCET HIV, 4(5), E195-E204. https://doi.org/10.1016/s2352-3018(17)30031-0

@article{2deeae30209042c082064e0ecd58bb06,

title = "Switching from tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study",

author = "C Orkin and E DeJesus and M Ramgopal and G Crofoot and P Ruane and A LaMarca and A Mills and B Vandercam and {de Wet}, J and J Rockstroh and A Lazzarin and Bart Rijnders and D Podzamczer and A Thalme and M Stoeckle and D Porter and HC Liu and A Cheng and E Quirk and D SenGupta and H Cao",

year = "2017",

doi = "10.1016/s2352-3018(17)30031-0",

language = "Undefined/Unknown",

volume = "4",

pages = "E195--E204",

journal = "LANCET HIV",

issn = "2352-3018",

publisher = "Elsevier Ltd.",

number = "5",

}

Orkin, C, DeJesus, E, Ramgopal, M, Crofoot, G, Ruane, P, LaMarca, A, Mills, A, Vandercam, B, de Wet, J, Rockstroh, J, Lazzarin, A, Rijnders, B, Podzamczer, D, Thalme, A, Stoeckle, M, Porter, D, Liu, HC, Cheng, A, Quirk, E, SenGupta, D & Cao, H 2017, 'Switching from tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study', LANCET HIV, vol. 4, no. 5, pp. E195-E204. https://doi.org/10.1016/s2352-3018(17)30031-0

Switching from tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study. / Orkin, C; DeJesus, E; Ramgopal, M et al.
In: LANCET HIV, Vol. 4, No. 5, 2017, p. E195-E204.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Switching from tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study

AU - Orkin, C

AU - DeJesus, E

AU - Ramgopal, M

AU - Crofoot, G

AU - Ruane, P

AU - LaMarca, A

AU - Mills, A

AU - Vandercam, B

AU - de Wet, J

AU - Rockstroh, J

AU - Lazzarin, A

AU - Rijnders, Bart

AU - Podzamczer, D

AU - Thalme, A

AU - Stoeckle, M

AU - Porter, D

AU - Liu, HC

AU - Cheng, A

AU - Quirk, E

AU - SenGupta, D

AU - Cao, H

PY - 2017

Y1 - 2017

U2 - 10.1016/s2352-3018(17)30031-0

DO - 10.1016/s2352-3018(17)30031-0

M3 - Article

SN - 2352-3018

VL - 4

SP - E195-E204

JO - LANCET HIV

JF - LANCET HIV

IS - 5

ER -

Orkin C, DeJesus E, Ramgopal M, Crofoot G, Ruane P, LaMarca A et al. Switching from tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study. LANCET HIV. 2017;4(5):E195-E204. doi: 10.1016/s2352-3018(17)30031-0